JAMA Ophthalmol
What's the latest evidence for Omega-3 supplements for dry eye disease?
May 24, 2024
The rTG form of ω-3 wasn't shown to be superior to grape-seed oil for ameliorating symptoms of dry eye disease (DED) with meibomian gland dysfunction (MGD) from baseline to 6 or 12 weeks, although no adverse events were observed from either supplement.
Study results:
- This double-masked, parallel-group RCT was conducted at 7 institutions from September 2020 to January 2023. Patients with DED associated with MGD were included and randomly assigned to the ω-3 group (received 1680 mg of eicosapentaenoic acid and 560 mg of docosahexaenoic acid), whereas those in the grape-seed group received 3000 mg of grape-seed oil daily.
- A total of 132 patients (mean age, 50.6 years; 78% female) were included in this study. The mean (SD) baseline Ocular Surface Disease Index (OSDI) scores of the ω-3 and grape-seed groups were 43.5 (16.5) and 44.1 (16.6), respectively.
- A total of 58 patients (87.9%) and 57 patients (86.4%) in the ω-3 and grape-seed groups, respectively, completed 12 weeks of follow-up.
- There were no differences in compliance with the dietary supplement intake between groups (ω-3, 95.8% and grape-seed, 95.4%). The OSDI (SD) change from baseline to 6 and 12 weeks was -20.5 (16.0) and -22.7 (15.7), respectively, in the ω-3 group and -15.1 (20.2) and -18.8 (21.7), respectively, in the grape-seed control group (difference at 6 weeks=-5.4; 95% CI, -12.15 to 1.33; P=0.12 and at 12 weeks=-3.9; 95% CI, -10.90 to 3.13; P=0.28).
- There were no changes in safety parameters or adverse events related to taking the dietary supplement in either group.
Source:
Eom Y, et al. (2024, May 16). JAMA Ophthalmol. Re-Esterified Triglyceride ω-3 Fatty Acids in Dry Eye Disease With Meibomian Gland Dysfunction. https://pubmed.ncbi.nlm.nih.gov/38753336/
TRENDING THIS WEEK